Clinical trial · Observational
Biomarkers of CASH
Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cavernous Angioma | Cavernous Hemangioma | ALIAS | 0.90 |
| Cerebral Cavernous Malformation | — | UNRESOLVED | — |
| Hemorrhagic Microangiopathy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| observational | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- label
- CA (non-CASH)
- description
- Cavernous Angioma (CA) without symptomatic hemorrhage cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting
- interventionNames
- Other: observational
- label
- CA (CASH)
- description
- Cavernous Angioma (CA) with Symptomatic Hemorrhage (SH) cases scheduled for evaluation by their neurology or neurosurgery teams in an inpatient or outpatient setting
- interventionNames
- Other: observational
- label
- Young with seizure
- description
- Young (\<30 years old) healthy control cohorts with seizures in the prior year
- interventionNames
- Other: observational
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Aim 1 and 2: Inclusion Criteria: 1. Clinical diagnosis of CA 2. age 18 or older 3. solitary or multiple 4. familial or sporadic 5. with or without prior symptoms Exclusion Criteria: 1. Prior excision of a solitary CA lesion 2. prior stereotactic radiosurgery or any brain irradiation 3. spinal cavernoma without brain lesion 4. other brain pathology unrelated to CA (demyelinating disease, brain tumor) 5. seizures or stroke unrelated to CA in the prior year 6. current pregnancy or within 6 months postpartum 7. reluctance to undergo venipuncture or donate blood specimen, or be called for clinical follow-up for up to one year 8. homeless or incarcerated persons, or other reason a subject will be unable/unlikely to be reached for follow-up Aim 3: Inclusion Criteria: 1. \< 30 years of age 2. one or more seizures (with or without medical therapy) in the prior year OR 1. \> 50 years of age 2. having received an MRI of the brain with SWI (susceptibility weighted imaging) sequences for any indication in the year prior to enrollment 3. No HMA on brain MRI SWI sequences OR 1. \> 50 years of age 2. having received an MRI of the brain with SWI sequences for any indication in the year prior to enrollment 3. Two or more microbleeds on SWI brain MRI sequences, adjudicated by neuroradiologist Exclusion Criteria: 1. concurrent brain disease or structural brain pathology 2. medical illness requiring hospitalization or surgery, seizure or stroke in the prior 12 months 3. active use of prescription medications in the prior 12 months 4. current pregnancy or within 6 months postpartum 5. reluctance to undergo venipuncture or donate blood specimen OR 1. concurrent brain disease or structural brain pathology 2. medical illness requiring hospitalization or surgery, or stroke in the prior 12 months other than seizure disorder 3. active use of prescription medications in the prior 12 months except anticonvulsants 4. current pregnancy or within 6 months postpartum 5. reluctance to undergo venipuncture or donate blood specimen OR 1. concurrent brain disease or structural brain pathology 2. medical illness requiring hospitalization or surgery within the prior year 3. any history of stroke or epileptic seizure within the prior year 4. current pregnancy or within 6 months postpartum 5. reluctance to undergo venipuncture or donate blood specimen OR 1. concurrent brain disease or structural brain pathology 2. medical illness requiring hospitalization or surgery within the prior year 3. any history of stroke or epileptic seizure within the prior year 4. current pregnancy or within 6 months postpartum 5. reluctance to undergo venipuncture or donate blood specimen
References
Publications (1)
- DERIVEDGirard R, Li Y, Stadnik A, Shenkar R, Hobson N, Romanos S, Srinath A, Moore T, Lightle R, Shkoukani A, Akers A, Carroll T, Christoforidis GA, Koenig JI, Lee C, Piedad K, Greenberg SM, Kim H, Flemming KD, Ji Y, Awad IA. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery. 2021 Feb 16;88(3):686-697. doi: 10.1093/neuros/nyaa478. PMID 33469662